Agilent Technologies got approval to expand the use of a cancer test to additional tumor types from the Food and Drug Administration.

The pros and cons of conducting PD-L1 testing in patients with non-small cell lung cancer. Hossein Borghaei, DO, MS: As far as PD-L1 testing, I’m pretty sure I know how it is at your center because we ...

NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS ...

NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to ...

Consistently, first-line trials of immune checkpoint inhibitors in combination with chemotherapy have demonstrated overall survival benefit for patients with metastatic gastroesophageal cancer.

Mortality within 30 days of receiving checkpoint inhibitor immunotherapy: An Australian multicenter review. % of LA pts I ordered the test 74 31.2 50, 100 % of LA pts another ONC ordered the test 11 ...

In Episode 42 of EC&M Asks features subject matter expert Tom Sandri, director of workforce development at Vector Power. He addresses common questions he receives about partial discharge (PD) testing ...